NEW YORK (GenomeWeb News) – Genomic Health's board has approved a $30 million share repurchase program, the Redwood City, Calif.-based firm said in a document filed with the US Securities and Exchange Commission today.

Repurchases made under the program will be funded using the firm's working capital. As of Sept. 30, Genomic Health had cash and cash equivalents, and investments and marketable securities totaling $127 million. It had about 30.8 million shares of common stock outstanding as of Nov. 30.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.